Bronchiolitis Obliterans Syndrome - Pipeline Insight, 2025

DelveInsight's, "Bronchiolitis Obliterans Syndrome - Pipeline Insight, 2025" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Bronchiolitis Obliterans Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Bronchiolitis Obliterans Syndrome: Understanding

Bronchiolitis Obliterans Syndrome: Overview

Bronchiolitis Obliterans Syndrome (BOS) is a form of chronic lung allograft dysfunction that affects a majority of lung transplant recipients and is the principal factor limiting long-term transplant survival. BOS is characterized by progressive airflow obstruction unexplained by acute rejection, infection, or other coexistent condition. Although BOS is a proven useful clinical syndrome that identifies patients at increased risk for death, its clinical course and underlying causative factors are now recognized to be increasingly heterogeneous. Regardless of the clinical history, the primary pathologic correlate of BOS is bronchiolitis obliterans, a condition of intraluminal airway fibrosis.

Signs and symptoms of Bronchiolitis Obliterans generally develop approximately two to eight weeks after exposure to toxic fumes or a respiratory illness. Early after the onset of BOS, a person may have no symptoms as he or she still has very good lung function. This is why it is so important to keep close follow-up with the transplant team and get frequent lung function monitoring after the transplant. Bronchiolitis obliterans may result from lung injury caused by a variety of different chemicals and respiratory infections. Inhaled chemicals known to irritate the lungs and lead to the condition include chlorine; ammonia; oxides of nitrogen or sulfur dioxide; welding fumes; or food flavoring fumes (such as diacetyl). Respiratory infections caused by respiratory syncytial virus, adenovirus, or Mycoplasma pneumonia have been linked with the condition.

BO is often undiagnosed or misdiagnosed as other wheezing syndromes. Asthma and BO both have similar auscultation and spirometric findings and Post Infectious Bronchiolitis Obliterans (PIBO) patients may be misdiagnosed as asthma. BO is often misdiagnosed as chronic obstructive pulmonary disease (COPD) or asthma, especially when there is no classic history of drug or toxic fume inhalation. There are multiple pathologic forms of BO, but the two most common categories are constrictive bronchiolitis and proliferative bronchiolitis.

Bronchiolitis Obliterans Syndrome (BOS) remains the major problem which cease long-term survival after lung transplantation. Treatment and prevention of BOS is quite challenging. Currently, there is no approved or standard treatment for BOS and successful treatment is defined as stabilization or reduction in the rate of FEV1 decline. An important focus of treatment of BOS patients is optimizing immunosuppression to prevent further lung allograft rejection. Current treatment consists primarily of augmenting immunosuppression by changing medications within therapeutic classes, by adding medications, or by applying non-medicinal immuno-modulating therapies.

"Bronchiolitis Obliterans Syndrome- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bronchiolitis Obliterans Syndrome pipeline landscape is provided which includes the disease overview and Bronchiolitis Obliterans Syndrome treatment guidelines. The assessment part of the report embraces, in depth Bronchiolitis Obliterans Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Bronchiolitis Obliterans Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Bronchiolitis Obliterans Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Bronchiolitis Obliterans Syndrome.

Bronchiolitis Obliterans Syndrome Emerging Drugs Chapters

This segment of the Bronchiolitis Obliterans Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Bronchiolitis Obliterans Syndrome Emerging Drugs

• Liposomal Cyclosporine A: Zambon Company

Liposomal Cyclosporine A for Inhalation (L-CsA-i) is a novel liposomal formulation of cyclosporine A developed for inhaled delivery to the lungs. Calcineurin inhibitors (CNIs), like cyclosporine A, are highly potent immunosuppressive drugs and a cornerstone of lung transplant medicine. L-CsA-i is administered via a drug-specific Investigational eFlow Technology nebulizer system (PARI Pharma GmbH). The investigational drug-device combination is designed to deliver L-CsA-i to the site of disease in the lung. It is currently being investigated in Phase III stage of development for the treatment of Bronchiolitis Obliterans Syndrome.

Bronchiolitis Obliterans Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Bronchiolitis Obliterans Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Bronchiolitis Obliterans Syndrome
• There are approx. 3+ key companies which are developing the therapies for Bronchiolitis Obliterans Syndrome. The companies which have their Bronchiolitis Obliterans Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Zambon Company.
• Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Bronchiolitis Obliterans Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bronchiolitis Obliterans Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bronchiolitis Obliterans Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bronchiolitis Obliterans Syndrome drugs.

Bronchiolitis Obliterans Syndrome Report Insights

• Bronchiolitis Obliterans Syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Bronchiolitis Obliterans Syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Bronchiolitis Obliterans Syndrome drugs?
• How many Bronchiolitis Obliterans Syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bronchiolitis Obliterans Syndrome?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Bronchiolitis Obliterans Syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Bronchiolitis Obliterans Syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Zambon Company
• OrphAI Therapeutics

Key Products

• Liposomal Cyclosporine A
• LAM-001